News from enanta pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 06, 2012, 17:21 ET

Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

 Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the...

Oct 17, 2012, 10:22 ET

Enanta's Lead Hepatitis C Compound ABT-450 Advances into a Phase 3 Clinical Trial through its Collaboration with Abbott

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious...

Sep 19, 2012, 08:03 ET

FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious...

Apr 04, 2012, 12:33 ET

Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL

Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious...

Feb 21, 2012, 07:01 ET

Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV

 Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious...

Oct 13, 2011, 08:00 ET

Enanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic

Enanta Pharmaceuticals, Inc., a clinical stage infectious disease biopharmaceutical company, announced today the award of a contract from the...

Sep 26, 2011, 09:02 ET

Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch

Enanta Pharmaceuticals, Inc. announced today that its lead development candidate from its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239,...

Mar 02, 2010, 09:30 ET

Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor...

Feb 18, 2009, 11:00 ET

Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor

Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration with a first-in-human...

Sep 15, 2008, 01:00 ET

Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced...

Apr 10, 2008, 01:00 ET

Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA

WATERTOWN, Mass., April 10 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, today...

Nov 01, 2007, 01:00 ET

Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies

WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors...

Jan 19, 2006, 00:00 ET

Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia

WATERTOWN, Mass., Jan. 19 /PRNewswire/ -- Enanta Pharmaceuticals announced today the initiation of a Phase 2 clinical trial for the treatment of...

Dec 20, 2005, 00:00 ET

Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd.

WATERTOWN, Mass., Dec. 20 /PRNewswire/ -- Enanta Pharmaceuticals today announced that it has received a milestone payment from its East Asia...

Mar 14, 2005, 00:00 ET

Enanta Pharmaceuticals Achieves Milestone in Collaboration with Shionogi & Co., Ltd., as Phase 1 Studies Initiate in Japan on EP-013420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic

WATERTOWN, Mass., March 14 /PRNewswire/ -- Enanta Pharmaceuticals today announced that it has received a milestone payment from its EP-013420...

Feb 22, 2005, 00:00 ET

Enanta Pharmaceuticals Appoints Pharmaceutical Veteran David Poorvin, Ph.D. to Board of Directors and Announces Key Hire to Clinical Development Team

WATERTOWN, Mass., Feb. 22 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. today announced that David Poorvin, Ph.D. has been named to the Company's...

Aug 31, 2004, 01:00 ET

Enanta Pharmaceuticals Raises $20 Million in New Financing and Initiates Phase 1 Clinical Trial on EP-013420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic for Community Respiratory Tract Infections

WATERTOWN, Mass., Aug. 31 /PRNewswire/ -- Enanta Pharmaceuticals today announced that it has raised $20 million in new financing. The Company...

Jul 27, 2004, 01:00 ET

Enanta Pharmaceuticals and Shionogi & Co., Ltd. Sign Agreement for Development and Commercialization of the First-in-Class Bridged Bicyclic Ketolide Antibiotic EP-013420 in Japan and East Asian Countries

WATERTOWN, Mass., July 27 /PRNewswire/ -- Enanta Pharmaceuticals today announced that Enanta and Shionogi & Co., Ltd. (Osaka, Japan) have...

Jan 14, 2004, 00:00 ET

Enanta Pharmaceuticals Secures $12 Million Financing Under New Management

WATERTOWN, Mass., Jan. 14 /PRNewswire/ -- Enanta Pharmaceuticals today announced new senior management and additional funding of $12 million to...

Oct 29, 2002, 00:00 ET

Enanta Pharmaceuticals Presents R&D at Mass Opps Investor Conference

WATERTOWN, Mass., Oct. 29 /PRNewswire/ -- Enanta Pharmaceuticals Inc. (www.enanta.com), a leading drug discovery company that focuses on...